Verònica Duarte retweetledi
Every diabetic patient deserves a triple shield: RASi + SGLT2i + nsMRA.
Early detection and rapid implementation = decades of kidney and cardiovascular protection.
@jlgorriz @IntDiabetesFed @scottisaacsmd @DanielJDrucker
@EndoConnect @IndiaESI @Rssdi_official
@kamleshkhunti @DrKhushboo_Endo
@AskDrShashank @banshisaboo
🧩 1. The Paradigm Shift — From Single to Triple Therapy
The cornerstone of CKD care in diabetes is evolving from traditional RAS inhibition alone (RASi) to triple kidney-protective therapy:
🩸 RASi – reduces intraglomerular pressure.
💧 SGLT2i – stabilizes eGFR, lowers CV events, and reduces albuminuria.
🌿 nsMRA (Finerenone) – offers additional cardiorenal protection by targeting inflammation and fibrosis.
This combination, supported by FIDELIO-DKD, FIGARO-DKD, and CONFIDENCE, can delay dialysis need by ≈12 years compared to dual therapy.
🧩 2. The Residual Risk Story
Even with RASi + SGLT2i, a significant residual risk persists — reflected in ongoing albuminuria and eGFR decline.
Adding Finerenone addresses this residual risk, cutting progression to kidney failure and CV events further.
The CONFIDENCE trial confirms the safety and efficacy of early combination: RASi + SGLT2i + nsMRA.
🧩 3. Real-World Gap — Where We Fall Short
🔍 Low albuminuria testing rates = missed early diagnosis of CKD.
⏳ Delayed initiation of SGLT2i or nsMRA = lost kidney years.
💊 Suboptimal dose titration and fear of hyperkalemia = underutilization of lifesaving therapies.
💬 Fragmented ownership — unclear responsibility between primary care, endocrinology, cardiology, and nephrology.
🧩 4. The Role of Primary Care — “The True Owner of CKD”
Over 90% of eligible T2DM–CKD patients can be diagnosed and managed in primary care.
Primary care physicians are perfectly positioned to:
Ensure routine eGFR + UACR testing.
Initiate RASi + SGLT2i early and add nsMRA when albuminuria ≥30 mg/g or eGFR ≥25 mL/min/1.73 m².
Promote healthy lifestyle, BP, and glucose optimization.
Refer to nephrology for eGFR <30 mL/min or rapidly progressive disease.
🧩 5. Safety Profile — Clinical Confidence in Combination
Triple therapy (RASi + SGLT2i + nsMRA) maintains a favorable safety profile:
⚡ Hyperkalemia events <2% discontinuation rate.
🚫 No increase in serious AKI or hypotension.
💚 Reduced BP, albuminuria, and mortality without increased hypoglycemia.
🧩 6. The Impact — Gaining a Decade of Kidney Life
Adding nsMRA can extend kidney survival by ~12 years before dialysis.
Each layer (RASi → +SGLT2i → +nsMRA) adds incremental, non-overlapping protection — a true “therapeutic staircase” to longevity.
Implementing triple therapy universally in eligible patients could cut cardiorenal events by >60%.
🧩 7. CME INDIA Take-Home Message
“Kidney protection in diabetes is no longer about slowing loss — it’s about preserving years of kidney life.”
🩺 Test for albuminuria early.
💊 Start RASi + SGLT2i together.
🌿 Add Finerenone without delay.
🤝 Integrate primary care, cardiology, and nephrology as partners.
🩶 CME INDIA ACTION POINT
Every diabetic patient deserves a triple shield: RASi + SGLT2i + nsMRA.
Early detection and rapid implementation = decades of kidney and cardiovascular protection.
kireports.org/article/S2468-…
(Source: Kidney International Reports, 2025; CONFIDENCE Trial; FIDELIO-DKD; FIGARO-DKD; KDIGO 2024 CKD Guideline)
@JasmineNephro @medflutter_ @drsthanus @DrAkhilX @pgMedicine
English
